NCT01731327View on ClinicalTrials.gov

A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Healthy
Interventions
DRUG

tofacitinib modified-release (MR) formulation

A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.

DRUG

tofacitinib modified-release (MR) formulation

A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01731327 - A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers | Biotech Hunter | Biotech Hunter